Recent News

• 11.03.2025 - Silence Disease Netherlands
• 10.01.2025 - 2020 Leqvio® (inclisiran) approved in the EU – first approved RNAi therapeutic in a prevalent disease (licensed to Novartis)
• 10.01.2025 - 2021Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisrian in Patients with hATTR PN
• 10.01.2025 - 2021 Leqvio® (inclisiran) approved in the US (licensed to Novartis)
• 10.01.2025 - 2021 Positive Topline Results from the ATLAS Phase 3 Study of fitusiran (licensed to Sanofi)
• 10.01.2025 - 2024 First POC for the first commercial use of a new enzymatic-ligation-based oligonucleotide manufacturing platform, advancing how siRNA-based medicines are made
• 10.01.2025 - 2021 Alnylam’s Norton, MA facility opens for siRNA Oligonucleotide Bulk Drug Substance API manufacturing
• 10.01.2025 - 2018 First ever RNAi therapeutic (ONPATTRO) approved
• 10.01.2025 - 2013 First POC for GalNAc conjugates for drug delivery

Recent Filings

• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 8-K Current report
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.03.2025 - 8-K Current report
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 144 Report of proposed sale of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.03.2025 - 4 Statement of changes in beneficial ownership of securities